Ligand Pharmaceuticals
LGND
211 hedge funds and large institutions have $1.17B invested in Ligand Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 72 increasing their positions, 71 reducing their positions, and 17 closing their positions.
100% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 17
55% more call options, than puts
Call options by funds: $4.48M | Put options by funds: $2.88M
23% more capital invested
Capital invested by funds: $947M → $1.17B (+$221M)
8% more funds holding
Funds holding: 196 → 211 (+15)
3.61% more ownership
Funds ownership: 90.13% → 93.74% (+3.6%)
1% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 71
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$12M |
| 2 |
SIMG
Stephens Investment Management Group
Houston,
Texas
|
+$11.3M |
| 3 |
Man Group
London,
United Kingdom
|
+$8.52M |
| 4 |
BlackRock
New York
|
+$7.15M |
| 5 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$7.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Chicago Capital
Chicago,
Illinois
|
-$7.6M |
| 2 |
ZCM
Ziegler Capital Management
Chicago,
Illinois
|
-$4.29M |
| 3 |
Prudential Financial
Newark,
New Jersey
|
-$3.09M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
-$2.04M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$1.82M |
LGND Hedge Fund Activity: Q4 2023 in Review
211 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q4 2023, worth a combined $1.17B — up 23% from $947M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new LGND positions and 17 closed out — a net gain of 17 holders — while 72 added to existing stakes and 71 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $12M. The largest seller was Chicago Capital, cutting an estimated $7.6M.
- 211 institutional investors held Ligand Pharmaceuticals (LGND) as of Q4 2023, up from 196 in Q3 2023.
- Funds reported $1.17B of Ligand Pharmaceuticals stock for Q4 2023, up 23% quarter-over-quarter.
- 34 funds opened new Ligand Pharmaceuticals positions in Q4 2023 and 17 closed out, a net change of +17 holders.
- The largest Ligand Pharmaceuticals buyer in Q4 2023 was Morgan Stanley, an estimated $12M added.
- The largest Ligand Pharmaceuticals seller in Q4 2023 was Chicago Capital, an estimated $7.6M sold.
Based on aggregated 13F filings for Q4 2023.